Navigation Links
Medarex Announces Allowance of Investigational New Drug Application for Company's First Antibody-Drug Conjugate, MDX-1203
Date:1/28/2009

PRINCETON, N.J., Jan. 28 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today the allowance of an investigational new drug (IND) application filed with the U.S. Food & Drug Administration (FDA) for MDX-1203, the Company's first Antibody-Drug Conjugate (ADC) candidate generated from its proprietary technology. MDX-1203 is comprised of a potent cytotoxic prodrug chemically linked with a fully human anti-CD70 antibody. CD70 is expressed in renal cell carcinoma (RCC), leukemias, lymphomas, and other cancers. The Phase 1 study will evaluate MDX-1203 for the treatment of advanced/recurrent RCC and relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL).

"Antibody-drug conjugates are another important and innovative therapeutic approach used to fight cancer by effectively and selectively killing tumor cells over-expressing specific tumor antigens, so we are extremely excited in achieving the IND filing for MDX-1203, the first candidate from our proprietary ADC technology platform," said Howard H. Pien, Chairman and CEO of Medarex. "We developed our ADC technology to have significant competitive advantages over existing technologies and the Phase 1 trial for MDX-1203 will be the first study to evaluate these potential benefits."

An open-label, multi-dose, dose-escalation Phase 1 clinical trial will be conducted in patients with RCC and NHL. This trial is designed to establish and evaluate the safety, tolerability and maximum tolerated dose, as well as preliminary distribution, metabolism and pharmacokinetics of MDX-1203.

About Medarex's Antibody-Drug Conjugate (ADC) Technology

Medarex has enhanced its core UltiMAb(R) antibody platform with a suite of technologies that optimize or augment the therapeutic activity of antibodies, and one important technology expansion is the company's pr
'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3

Related biology technology :

1. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
2. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex Announces Election of Marc Rubin as New Board Member
7. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
8. Medarex Announces Completion of Sale of Shares in Genmab A/S
9. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
10. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... York investment bank KTA Capital,s client Neuren ... mil convertible note private placement with a U.S...s arranged by KTA Capital as Neuren,s exclusive pl... New York (PRWEB) November 23, 2009 -- The inde...("KTA Capital") has announced that its c...
(Date:11/24/2009)... Sigma-Aldrich Corporati...AQ OMX conference on Tuesday, December 1st at 1:45...ies may listen via live audio broadcast over the I... a a ldrich.com/ . Users can click the "Webcas...-Aldrich: Sigma-Aldrich is a leading Life Scienc...
(Date:11/24/2009)..., Nov. 24 NeurogesX, Inc...cused on developing and commercializing novel pain...y DiTonno, President and Chief Executive Officer, ...affray Health Care Conference, to be held December...k, New York. ,, Mr. DiTonno and Stephen Ghigli...
(Date:11/24/2009)...y endpoint has been met for patients with advanced... QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - AEt... "Company"), a global biopharmaceutical company fo...ounced positive efficacy data from a Phase 2 study...ZS-108 (formerly AN-152), in patients with advance...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...4 Nitec Pharma AG today,announced that the US Foo...nvestigational New Drug (IND) application submitte...ent for Lodotra. Following the positive results o...dministration of Prednisone in Rheumatoid Arthriti...ization in Europe. The FDA,s,acceptance of the IND...
...merican governments biodefense efforts, the potent...eak remains a significant concern, six years after...after 9/11. , Now, researchers at the University...st complete picture of how anthrax-causing bacteri...their supposed attackers during the crucial first...
...nt place out beyond the horizon. Even as you read...ing the worlds waterways and oceans, not to mentio...in and out of ports, loading, unloading, changing ...on to the next. , , In what can be a very murky...anifests, and dockhands who change out faster than...
Other Biology Technology:Nitec's IND Application for Clinical Development With Lodotra Accepted by the FDA 2Nitec's IND Application for Clinical Development With Lodotra Accepted by the FDA 3Taming the anthrax threat 2Taming the anthrax threat 3Out beyond the horizon 2Out beyond the horizon 3
(Date:11/24/2009)...ease is available in Spanish . , The presen...els of inflammatory substances in the blood, hinde...wn by a research project of the University of Nava...tist at the School of Pharmacy. , The project, e...relation to the control of body weight and inflamm...
(Date:11/23/2009)...n, D.C. The community-associated strain of the de...sistant to most common antibioticsposes a far grea...ing its way into hospitals, according to a study i...ses . , The new threat is easily picked up in f...nd has increased the overall burden of MRSA within...
(Date:11/23/2009)..., November 23, 2009 - The time of day matters to f...ew paper produced by a research team led by Profes...rough,s vice-principal for research and colleagues...the St. George campus. , Capitalizing on their...tree, the research team examined how poplar trees ...
Breaking Biology News(10 mins):It can be predicted the reaction obese patients will have to a diet 2New study finds MRSA on the rise in hospital outpatients 2Time of day matters to thirsty trees, U of T researcher discovers 2Cell Therapeutics Inc 28CTI 29 to Present at 8th Annual BIO Investor Forum 5673 1MedAppz Signs Agreement with MedAssets to Offer SAAS based Electronic Health Record to MedAssets 26apos 3B Non acute Customers 60045 1MedAppz Signs Agreement with MedAssets to Offer SAAS based Electronic Health Record to MedAssets 26apos 3B Non acute Customers 60045 2Wellcome Trust funds dengue fever research in Leuven 10516 1Wellcome Trust funds dengue fever research in Leuven 10516 2
...TIN, TexasAn international team of conservation sc...ited States, including University of Texas at Aust...vation tactics, such as assisted migration, in the... They report their policy ideas in a paper publish...ors argue that both the rapid rate of climate chan...
...LINAS, CA - The lettuce cut and packaged for food ...nt component of the produce industry. Lettuce is h...essing further shortens its shelf life. , Packagi...eable plastic films extends shelf life via a techn...uccess of modified-atmosphere (MA) packaging for l...
...R-SHEVA, ISRAEL - The news that olives are sources...the luscious, versatile fruits. Olives have become...ers, spreads, and additions to salads and sauces. ...star status in kitchens around the world. , The o...out by modern science, as studies of olive-consumi...
Other Biology News:Global warming experts recommend drastic measures to save species 2Good breeding increases shelf life 2Saltwater olives 2
GeneAmplimer HIV-1 Control Reagents from Applied Biosystems
... Tissues are selected tissues from mouse, rat, and...araffin, sectioned and mounted onto slides. After ...tissue RNA localization by in situ hybridization. ... situ hybridization using both 35S-labeled and non...
Human Angiogenesis Array 1 Kit, Quantibody from Raybiotech, Inc.
Vybrant Multicolor Cell-Labeling Kit *DiO DiI DiD solutions 1 mL each* from Molecular Probes (Invitrogen)
Biology Products: